BriaCell Therapeutics Corp. (BCTXW) Stock Price, Financials & Summary

Price chart

Feb 12Feb 18Feb 23Feb 26Mar 10Mar 13Mar 18Mar 23

Key dataMar 23, 2026

Open$0.00

From 52W high−99.47%

Volume186080.00

Market cap$1695.52

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataMar 23, 2026

Open

$0.00

From 52W high

−99.47%

Volume

186080.00

Market cap

$1695.52

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.1x

P/E (TTM)

—

RSI (14)

26.8

MomentumView details →

1D Return

−0.00%

YTD Return

−98.30%

SummaryUpdated Apr 1, 2026

BriaCell Therapeutics Corp. (NASDAQ:BCTX) is a Canadian immuno-oncology biotechnology company founded in 2012 and headquartered in West Vancouver, Canada. The company went public on March 14, 2012, and focuses on developing innovative immunotherapies specifically designed to treat various forms of cancer. BriaCell operates as a clinical-stage biopharmaceutical company with no current commercial products, dedicating its resources to advancing novel cancer treatment approaches through its proprietary immunotherapy platform.

Ask drillr about BriaCell Therapeutics Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

1.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−109.39%

ROA (TTM)

−100.67%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

−68.39%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−44.42%

MomentumView details →

1D Return

−0.00%

YTD Return

−98.30%

1Y Return

−98.94%

RSI (14)

26.8

vs 50D SMA

−94.49%

vs 200D SMA

−97.90%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

10.10x

Quick Ratio

10.10x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$315.47

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−46.83M

Op. CF (TTM)

−36.95M

Latest newsMore news →

BriaCell Therapeutics Corp. completed a best-efforts follow-on offering of 1,449,300 common shares at $3.25 per share for gross proceeds of $4.71 million, with ThinkEquity LLC as placement agent.110d ago

Similar companies

Lipella Pharmaceuticals Inc.LIPO CERo Therapeutics Holdings, Inc.CEROW Aditxt, Inc.ADTX Dermata Therapeutics, Inc.DRMAW Abpro Holdings IncABPWW Moolec Science S.A.MLECW Find similar companies →

Latest newsMore news →